Race Against The "New Crown" Virus: Multiple Antiviral Drugs For Clinical Treatment

The new coronavirus has been infected with pneumonia. However, there are no drugs for clinical treatment of 2019-nCoV yet. However, many research teams at home and abroad are stepping up testing different clinical treatment drugs and regimen.

In February 4th, Li Lanjuan, member of the Chinese Academy of engineering and member of the national expert group of Health Protection Committee, announced the latest research results in Wuhan on treating pneumonia caused by new coronavirus infection. According to preliminary tests, in vitro cell experiments showed that abdor and dulavavir could effectively inhibit the new crown virus.

On the afternoon of the same day, Sun Yanrong, deputy director of the Biotechnology Center of the Ministry of science and technology, responded to the recent focus drug Remdesivir Reed at the national health and Health Committee's news conference. "Domestic scientific research units showed excellent in vitro activity in the process of virus screening in vitro. Recently, the State Food and drug administration has informed applicants that China-Japan Friendship Hospital and the Chinese Academy of medical sciences can carry out clinical trials. The drugs are expected to arrive in China on the afternoon of 4, which means more patients will be using the drug.

According to incomplete statistics of twenty-first Century economic report, as of February 4th, a variety of antiviral drugs, proprietary Chinese medicines and other treatment options have been put into use or will soon be used for clinical treatment. According to the China clinical trial registration center, there are 32 clinical trials registered as "new coronavirus", including drugs such as Barlow Shah Vee, flapiwei, lorcavir / ritonavir (Ke Lizhi), chloroquine, and raviravir / corbistar, with Lianhua Qingwen, Xuebijing injection and glucocorticoid.

Even so, large-scale clinical trials have yet to demonstrate the effectiveness of any of these drugs against the "new crown" virus.

Antiviral drugs

In February 4th, the national drug regulatory agency (CDE) approved Reed China-Japan Friendship Hospital's application for clinical trials. According to the previous case, a new Wuhan crown champion has improved significantly after using Reed West Wei. In twenty-first Century, the economic news reporter verified the lead of the clinical trial Cao Bin and his team members. As of press release, no reply was received.

Reed Wei was originally a drug developed by Gillie for the Ebola virus. The first case of a new coronavirus in the United States was treated with Remdesivir after exacerbation of the disease. Symptoms improved significantly the next day. "As of January 30th, the patient was still hospitalized. But he is no longer fever, except cough, all symptoms have been relieved, and the degree of cough is decreasing.

Remdesivir is a nucleotides analogue prodrug that inhibits RNA dependent RNA synthetase (RdRp). It is presumed that the new crown virus is also effective because of the same RdRp in the new crown virus. Remdesivir has not been very effective in Ebola, but gilid has started a pre clinical study of other coronavirus infections, including SARS and MERS.

Another antiviral drug that has been carrying out clinical trials is Aibo's "Zhi Zhi", which is the antiviral treatment plan of the new coronavirus pneumonia diagnosis and treatment plan (trial version fourth). It can be tested with alpha interferon inhalation (adult 5 million U each time, adding Sterile Water for Injection 2ml, 2 times daily); and ritonavir / ritonavir (200mg/50 Mg, 2 tablets each time, two times a day.

In 2000, FDA approved the treatment of AIDS infection in China, and was approved in 2008 in China. In February 4th, AI Bo Wei said to the twenty-first Century economic report that "current clinical research is initiated by researchers all over the world. According to the guidelines issued by the Health Council, we donated tens of millions of RMB worth of drugs to the trial. At present, our reserves and supplies are adequate, which can fully guarantee the supply of free treatment for AIDS in the country, and also meet the needs of the state to support the current attempt to fight the new coronavirus.

It is also one of the drugs used by the Ministry of health in Thailand for the treatment of new crown patients. However, the scheme is also too few cases, the individual situation is strong, and the universal utility remains to be tested. Academician Li Lanjuan said that the anti AIDS drug "Zhi Zhi" is not effective in treating pneumonia caused by new coronavirus, and has toxic side effects.

More drugs on the road

In February 4th, apart from the drugs that were still in the treatment plan, the government gave four "potentially effective drugs".

Two of them are abydor and dulavavir released by the academician Li Lanjuan. Li Lanjuan said that according to preliminary tests, in vitro cell experiments showed: (1) at 10~30 micromolar concentration, Abi Dore could effectively inhibit the coronavirus to 60 times, and significantly inhibit the viral effect on cells. (2) at 300 micromolar concentration, Da Lu Wei significantly inhibited virus replication. Compared with the untreated group, the inhibition efficiency was 280 times.

Abydo (duer) is an antiviral drug. The main indication is influenza A and B influenza viruses, and it may also have some antiviral activities against other respiratory viruses. According to the data of the State Administration of drug administration, there are 7 records of Arbidol Tablets, granules, capsules and dispersible tablets, which include Arbidol Tablets pharmaceutical, Jiangsu Wuzhong medicine, Shijiazhuang Zhong Shuo pharmaceutical, and Xian Sheng Pharmaceutical Co., Ltd. Another Da Lu Wei (trade name: Pu se Li) is an anti HIV drug, from Yang Sen company.

In addition, Sun Yanrong mentioned two other drugs in the above press conference. "We also found a group of listed drugs with antiviral activity in chloroquine phosphate, de la virion, and proprietary Chinese medicines. For example, chloroquine phosphate has been listed as an antimalarial drug and has shown excellent anti novel coronavirus activity in in vitro studies. Now we are also pushing forward animal experiments and clinical trials. Chloroquine phosphate has been shown to be effective in the treatment of this new coronavirus pneumonia in clinical trials. Of course, we will further study the system. "

According to the State Food and drug administration, there are 30 records of Chloroquine Phosphate Tablets, involving Shanghai Qingping pharmaceuticals, Shanghai Xinyi Tian Ping pharmaceuticals, Shanghai medicine and Western medicine, Sichuan Sheng and pharmaceutical industry, Guangzhou Baiyun Mountain, Shijiazhuang Ouyi, Kunming Pharmaceutical Group and other companies.

It is a broad-spectrum antiviral drug, and no drug is currently available in China. In 2016, Hai Zheng pharmaceutical obtained the patent license of China in France. In February 4th, Hai Zheng pharmaceutical announced that it will produce according to generic drugs, indications for the treatment of new or recurrent influenza in adults (except for other anti influenza drugs that are ineffective or ineffective). Up to now, the State Drug Administration has not yet formally accepted the registration information of the company's products, and the company has not received the permission of the special examination and approval. "

For the development of new crown drugs, Sun Yanrong said, "we will increase the cure rate and reduce the fatality rate as the top priority of emergency research. The most important thing is that systematic and large-scale screening has been made in the listed and ongoing clinical trials. Drug screening is yet to be further validated in clinical practice. It is necessary to determine the effectiveness of the new coronavirus infection in pneumonia on the premise of ensuring safety. In addition, in the emergency projects launched by the Ministry of science and technology, scientists actively promote research and exploration including the clinical efficacy of convalescent plasma and stem cells in severe treatment.

?